Substances · Phenethylamine derivatives
4F-MPH
- Preferred name
- 4F-MPH
- IUPAC name
- methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate
- Parent CAS number (reference)
- 1354631-33-6
- Molecular formula
- C14H18FNO2
- Molecular weight
- 251.3 g/mol
- InChIKey
- XISBAJBPDVRSPG-CHWSQXEVSA-N
- PubChem
- CID 52944002
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
4-Fluoromethylphenidate 4FMPH 4F MPH threomethylphenidate-4F
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
4F-MPH
Receptor Telemetry & Mechanism of Action
4F-MPH is a fluorinated analogue of methylphenidate and a dopamine/norepinephrine reuptake inhibitor, not a substrate releaser like amphetamine. Fluorination increases potency relative to methylphenidate, which is why the PsychonautWiki common oral band is only 10–15 mg. The reference IUPAC is the (2R,2'R) threo form, methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate. The subjective feel is focused stimulation, anxiety at the top of the range, and a long residual tail rather than an entactogenic roll.
Biotransformation & Active Metabolites
Like methylphenidate, the ester can be hydrolyzed to the inactive ritalinic-acid analogue. It is not a prodrug of amphetamine and it is not isopropylphenidate.
Temporal Pharmacokinetics
Potent, functional NDRI stimulant. Focus and wakefulness, little serotonin warmth, a sharp anxiety edge when pushed, and hours of residual stimulation.
- Onset 30–60 minutes
- Peak Window 2–4 hours
- Total Window 4–8 hours
- Residual / Half-Life After-effects 5–10 hours. The ester hydrolysis product is not an active 'second wind'.
Threshold under 5 mg, light 5–10 mg, common 10–15 mg, strong 15–20 mg, heavy above 20 mg. The entire useful span is about 15 mg wide. mucosal common is 8–14 mg and shorter; it is harsher and not required to describe the oral window. A methylphenidate-sized dose is already a heavy 4F-MPH dose.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
under 5 mg
A small increase in alertness.
Slight dry mouth.
5–10 mg
Functional focus and wakefulness with little mood elevation.
Appetite suppression and a mild pulse increase.
10–15 mg
Clear stimulation, task focus, and talkativeness that can tip into scatter.
Tachycardia, cold hands, bruxism, and sweating.
15–20 mg
Anxiety, forced wakefulness, and irritable focus rather than better concentration.
Pronounced vasoconstriction, tremor, and a long insomnia tail.
20 mg+
Agitation, paranoia, and compulsive repeated exposure.
Hypertensive strain, chest discomfort, severe insomnia, and seizure risk with tramadol or an MAOI.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Blocking monoamine breakdown while a releaser or a catecholamine uptake inhibitor is active can produce a hypertensive crisis and, for the serotonergic members, serotonin toxicity.
Adds extreme vasoconstriction and seizure risk on top of an already raised heart rate and blood pressure.
Both lower the seizure threshold. Tramadol also adds serotonin reuptake inhibition, which is dangerous with the serotonergic releasers in this set.
Elevated Hazard — Avoid
Additive tachycardia, hypertension, bruxism, and post-session anxiety without restoring a faded peak.
The stimulant hides sedation. When it drops, the depressant remains.
Caution / Receptor Attenuation
Additive norepinephrine/dopamine reuptake block. IPPH common is 15–25 mg and is not a top-up for 4F-MPH.
May change how fast the oral dose arrives. It does not make a 20 mg dose a light one.
Structural Isomer & Sibling Comparison
4F-MPH is the potent fluorinated methylphenidate: common oral 10–15 mg, heavy above 20 mg, 4–8 hours plus a 5–10 hour tail. IPPH is the isopropyl ester, less sharp, common 15–25 mg, total about 3.5–6 hours. Methylphenidate tablet habits are larger than this compound's heavy line. Neither phenidate is an entactogen; 4-FA and 5-MAPB are the wrong family and the wrong interactions.
Physicochemical Stability & Storage
Form: White, off-white, or pale tan crystalline powder, shards, or clumps as the hydrochloride or another salt. Not a plant blend. · Hydrochloride salts dissolve in water and alcohols. Succinate salts of the benzofurans also dissolve in water but contain less active amine per milligram.
Airtight, cool, dry, and dark. Some salts are hygroscopic and clump. A clump is not a reason to guess the mass.
Cross-Tolerance & Dependence Profile
Stimulant tolerance with cross-tolerance to other NDRIs and amphetamines. Halves over roughly 3–7 days and approaches baseline in 1–2 weeks of abstinence. Psychological dependence and a crash of fatigue and low mood are expected. It is not an opioid withdrawal. Chasing the 2–4 hour peak with a second 10 mg is how the heavy zone is reached.
Chemical Architecture & Structural Profile
4F-MPH (methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate) is a reference compound belonging to the Phenethylamine derivatives class, characterized by the molecular formula C14H18FNO2 and a molar mass of 251.3 g/mol. The parent molecule is indexed under CAS registry number 1354631-33-6 and in the NCBI PubChem database as CID 52944002 (Standard InChIKey: XISBAJBPDVRSPG-CHWSQXEVSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), 4F-MPH is indexed within the Substituted phenidates structural group. Substituted phenethylamine derivative; documented reference precautions highlight hazardous interactions with MAOIs, tramadol, and lithium salts. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- legislation.gov.uk — Misuse of Drugs Act 1971 & Psychoactive Substances Act 2016 — The National Archives (UK) (2026-11-12)